Fragment growing to retain or alter the selectivity of anchored kinase hinge-binding fragments

The activity patterns of kinase hinge-binding fragments can be retained or redirected in fragment growing strategies. Targeting conserved kinase features preserved the selectivity pattern of a PKB hinge-binding fragment over a 5000-fold increase in potency, while late-stage modification of a CHK1 hinge-binding fragment substantially changed the pattern.

[1]  Zhizhou Fang,et al.  Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features. , 2013, ACS chemical biology.

[2]  C. E. Allen,et al.  Synthesis and evaluation of heteroaryl substituted diazaspirocycles as scaffolds to probe the ATP-binding site of protein kinases. , 2013, Bioorganic & medicinal chemistry.

[3]  C. Dasanu,et al.  Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use , 2012, Expert opinion on drug safety.

[4]  D. Fabbro,et al.  Targeting cancer with small-molecular-weight kinase inhibitors. , 2012, Methods in molecular biology.

[5]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[6]  Roland L. Dunbrack,et al.  A Highly Selective Dual Insulin Receptor (IR)/Insulin-like Growth Factor 1 Receptor (IGF-1R) Inhibitor Derived from an Extracellular Signal-regulated Kinase (ERK) Inhibitor* , 2013, The Journal of Biological Chemistry.

[7]  G. Aherne,et al.  Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt)† , 2010, Journal of medicinal chemistry.

[8]  Gianni Chessari,et al.  From fragment to clinical candidate--a historical perspective. , 2009, Drug discovery today.

[9]  K. Shokat,et al.  Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.

[10]  P. Bamborough.  System-based drug discovery within the human kinome , 2012, Expert opinion on drug discovery.

[11]  Ian Collins,et al.  Identification of inhibitors of checkpoint kinase 1 through template screening. , 2009, Journal of medicinal chemistry.

[12]  Gary Box,et al.  Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing , 2011, Journal of medicinal chemistry.

[13]  Kevan M. Shokat,et al.  Chemical genetic discovery of targets and anti-targets for cancer polypharmacology , 2012, Nature.

[14]  Ian Collins,et al.  Measuring and interpreting the selectivity of protein kinase inhibitors , 2009, Journal of chemical biology.

[15]  Ian Collins,et al.  Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration. , 2008, Journal of medicinal chemistry.

[16]  B. Shoichet,et al.  A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.

[17]  Simone Sciabola,et al.  High-Throughput Biochemical Kinase Selectivity Assays: Panel Development and Screening Applications , 2009, Journal of biomolecular screening.

[18]  Paul Bamborough,et al.  Selectivity of kinase inhibitor fragments. , 2011, Journal of medicinal chemistry.

[19]  Ian Collins,et al.  Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design. , 2007, Journal of medicinal chemistry.

[20]  R. Morphy.  Selectively nonselective kinase inhibition: striking the right balance. , 2010, Journal of medicinal chemistry.

[21]  K. Shokat,et al.  Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases , 2008, Nature chemical biology.

[22]  W. Janzen,et al.  High-throughput screening of the cyclic AMP-dependent protein kinase (PKA) using the caliper microfluidic platform. , 2009, Methods in molecular biology.